OUR HISTORY

The history of CellTherX dates to May of 2010 when Dr. Barry Markman, a board certified plastic surgeon, in Las Vegas, NV submitted his first patents for Microsurfacing of regenerative tissue grafts. He formed Markman Biologics Corporation in December of 2017. Most recently in 2024, CellTherX Corp was created as a Texas corporation and is the patent holding entity of intellectual property patents that pertain to Microsurfacing of smooth surface reconstructive grafts, including but not limited to, acellular dermis, split thickness skin, and decellularized amnion/chorion tissue.

CellTherX currently licenses its Intellectual Property in the dental market segment to Osteogenics. Their product is called Cytoplast Microderm and is marketed to Dentists, Periodontists, and Oral Surgeons. CellTherX recently completed a study led by Dr. Michael McGuire of the iMc Institute in Houston, TX. The study confirms the benefits of Microsurfaced tissue over smooth surface allografts in periodontology. The study is scheduled for publication in the International Journal of Periodontology in the second half of 2024.

CellTherX’s focus is to continue to partner with Tissue Banks to produce best-in-class reconstructive tissue grafts and improve the wound healing processes;  thereby honoring the life-saving gift of human tissue donation.

In addition to the current mission to enhance wound healing and improve the lives of patients who must undergo traditional reconstructive surgery; the company’s future development plans are to pursue partners in the emerging cell and gene therapy industry.